Oncological outcomes of radical prostatectomy in very high-risk patients according to STAMPEDE criteria: does local treatment alone still have a place in the era of intensified systemic therapies?
Michaël Baboudjian(Assistance Publique Hôpitaux de Marseille), Guillaume Ploussard(Yves Rocher (France)), Bastien Gondran‐Tellier(Aix-Marseille Université), Jean B. BEAUVAL(Hôpital de la Croix-Rousse), Alexandre Fourcade(Centre Hospitalier Régional Universitaire de Brest), Alberto Martini(The University of Texas MD Anderson Cancer Center), Giuseppe Simone(Istituti di Ricovero e Cura a Carattere Scientifico), Olivier Windisch(Hôpital Beau-Séjour), Vito Lacetera(Ospedali Riuniti Marche Nord), Alexandre Peltier(Institut Jules Bordet), Roderick C. VAN DEN BERGH(St. Antonius Ziekenhuis), Romain Diamand(Institut Jules Bordet), G. Fiard(Centre Hospitalier Universitaire de Grenoble), Daniel Benamran(University Hospital of Geneva), Thierry Roumeguère, Jean B. ROCHE(Clinique du Sport), Alae Touzani(Lyon Genou Centre Albert Trillat)
Cited by 2
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease
|Annals of the Rheumatic Diseases|2001|287
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection
|European Urology|2019|212